Wall Street is positive on BioCardia Inc (BCDA). On average, analysts give BioCardia Inc a Strong Buy rating. The average price target is $15.875, which means analysts expect the stock to climb by 581.33% over the next twelve months.
That average ranking earns BioCardia Inc an Analyst Rating of 80, which is better than 80% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers.
InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.
What's Happening With BioCardia Inc Stock Today?
BioCardia Inc (BCDA) stock has fallen -3.53% while the S&P 500 has risen 0.67% as of 2:26 PM on Thursday, Sep 24. BCDA has fallen -$0.09 from the previous closing price of $2.41 on volume of 100,475 shares. Over the past year the S&P 500 is up 9.17% while BCDA has fallen -46.92%. BCDA lost -$2.28 per share the over the last 12 months.